Systemic Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.4
In brief
ASCO releases updated living guideline for systemic therapy in metastatic castration-resistant prostate cancer
The new ASCO living guideline version 2026.1.4 offers the latest, continuously revised recommendations for treating metastatic castration-resistant prostate cancer as evidence evolves. It is intended to inform, not replace, clinicians' judgment and highlights that individual patient factors may require deviation from the standard recommendations.
- Journal
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology (Q1)
- Published
- 6 August 2026
- Study design
- Practice guideline / consensus
- Evidence level
- Level 1, High (CEBM 1c)
- Authors
- Mary-Ellen Taplin, Rahul A Parikh, R Bryan Rumble, Syed Arsalan Ahmed Naqvi, Fouad Nahhat, Mariane Fontes Dias, et al.
- PMID
- 42561262
- DOI
- 10.1200/JCO-26-01898
Why clinicians should know about it
- Picked for Urology (top studies of the week, 9 August 2026): ASCO living guideline for mCRPC systemic therapy
Abstract
[Box: see text]Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix I and Appendix II). Updates are published regularly and can be found on the ASCO Publications website.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.